MediciNova (MNOV) +23.8% premarket after announcing its MN-166 drug as a treatment for...

|By:, SA News Editor

MediciNova (MNOV) +23.8% premarket after announcing its MN-166 drug as a treatment for methamphetamine dependence was granted fast-track status by the FDA.